Pre-Discovery — quick readiness check to confirm whether a short discovery is worthwhile

• What is the target regulatory submission or approval timeframe that is driving this transfer? Options: Within 3 months, 3–6 months, 6–12 months, 12+ months, No fixed date / exploratory
• Which regulatory authority or authorities are primary for that filing? Options: FDA, EMA, PMDA, Other (specify below), Not yet defined

Budget and commercial readiness

• Is there an allocated budget range for the transfer and validation work? Options: Under $100k, $100k–$500k, $500k–$1M, $1M–$3M, Over $3M, No budget allocated yet / exploratory
• If there are commercial constraints or a preferred procurement vehicle (PO, milestone payments, MSA, etc.), please summarize them briefly.

Decision-makers and technical ownership

• Who are the primary decision-maker(s) for selecting a transfer partner? (select all that apply) Options: Head of CMC, VP Manufacturing / Operations, Head of Technical Operations, Head of Supply / Procurement, External licensing partner, Other (specify below)
• Where will technical release and regulatory sign-off reside once validation is complete? Options: Buyer central QA/CMC signs release, Receiving site QA signs release, Shared — both buyer and receiving site approvals required, Undecided / varies by region

Transfer urgency and product fit

• How would you describe the urgency to complete the transfer? Options: Critical — filing or supply gap within 3 months, High — required 3–6 months, Moderate — 6–12 months, Planning — 12+ months, Exploratory / no fixed deadline
• Briefly describe the product type and any key complexities we should know up front (small molecule, biologic, sterile injectable, aseptic fill, controlled substances, human‑derived materials, cold chain, etc.).

Snapshot: the transfer you need right now

• Start by describing the immediate trigger for this transfer, in one sentence.
• When is your target regulatory filing or commercial go-live date? Options: Within 3 months, 3 to 6 months, 6 to 12 months, 12+ months, No firm target yet
• Which of these reasons best describes the primary driver for this transfer? Options: Regulatory filing deadline, Site capacity constraint, Second-source requirement, Licensing/partner replication, Cost or supply resilience
• How urgent is this transfer on a scale where 1 is routine and 5 requires immediate mobilization? Options: 1 - Routine planning, 2 - Low priority, 3 - Active planning, 4 - High priority, 5 - Immediate mobilization
• Who will be the primary decision-makers we need to engage during technical assessment and contracting? Options: Head of CMC, VP Manufacturing/Technical Ops, Head of QA/Regulatory, Procurement lead, Other - will provide names
• If the timeline moves by four weeks, what consequence is most likely for your program? Options: Minor delay, manageable, File date postponement, Material supply risk, Regulatory window missed, Commercial launch impact

Where process detail is hiding risk

• Which undocumented step in your sending process would most surprise a receiving team?
• Walk me through the end-to-end batch flow from start of material creation to final release, calling out unit operations and in-process holds.
• How many distinct unit operations or handoffs does a typical batch require? Options: 1-3, 4-6, 7-10, More than 10
• List the routine in-process controls and analytical tests performed during release, and note any that are non-standard.
• When was the last formal process characterization report produced for this product? Options: Within 6 months, 6-12 months, 12-24 months, More than 24 months, No formal report available
• If a critical quality attribute fails to reproduce at the receiving site, which response would you prefer: pause transfer, implement defined change control, or accept a conditional path? Options: Pause transfer and investigate, Implement predefined change control and continue, Accept conditional path with added monitoring

The molecule and its tricky bits

• Point to the molecule attribute that has caused the most validation failures in past transfers.
• Describe the molecule class and formulation type, select the closest match. Options: Small-molecule immediate release, Small-molecule controlled release, Biologic, non-sterile, Biologic, sterile injectable, Cytotoxic or highly potent, Other
• Rate the product's sensitivity to scale, shear, temperature, and hold time on a 1 to 5 scale, where 5 is highly sensitive. Options: 1 - Not sensitive, 2 - Mild sensitivity, 3 - Moderate sensitivity, 4 - High sensitivity, 5 - Extremely sensitive
• List any excipients, solvents, or carriers that require special handling, containment, or licensed use.
• Choose the contingency you are willing to accept if accelerated stability does not meet target: additional stability data, formulation modification, or delayed filing. Options: Additional stability data (longer study), Formulation modification, Delay filing, Other contingency

Receiving site capabilities, where the handoff meets reality

• Point to a receiving-site limitation that would make you stop the transfer today.
• Select the manufacturing platforms available at the receiving site, including reactor types, fermenters, isolators, and filling lines. Options: Stirred-tank reactors, Fixed-bed reactors, Bioreactors (single-use), Bioreactors (stainless), Aseptic filling isolator, Blow-fill-seal, High-potency containment
• Report the number of comparable product transfers the receiving site completed in the last 24 months. Options: 0, 1-3, 4-7, 8-15, More than 15
• Who owns equipment qualification and do they have documented IQ, OQ, PQ protocols and historical experience? Options: QA/Validation team, Engineering team, Shared QA and Engineering, External contractor, Not documented
• Are on-site analytical labs capable of method development and sample turnaround within your filing timeline? Options: Yes, full capability, Limited capability, some outsourcing needed, No, full external testing required
• Would outsourcing a required release test or qualifying an alternative method be acceptable if in-house testing is unavailable? Options: Outsource test, Qualify alternative method at site, Require in-house capability before proceeding

Who's accountable when things go sideways

• Identify the person who will sign final batch release and the level of authority they have to delay release.
• Name the internal teams that must be engaged during transfer, for example CMC, QA, QC, engineering, regulatory, and supply-chain. Options: CMC/Process Science, Quality Assurance, Quality Control, Engineering/Facilities, Regulatory Affairs, Supply Chain/Materials
• State the cadence of technical governance meetings and who typically chairs them. Options: Weekly, Biweekly, Monthly, Ad hoc as issues arise
• Provide the day-to-day contact at your organization for pilot coordination and issue triage.
• Walk me through the escalation path for an out-of-specification event or deviation discovered during pilot batches.

Hidden constraints that kill timelines

• Identify a regulatory or contractual gate that could stop the project before execution.
• Are there pending inspections, legal holds, or import/export licenses that could delay sample movement or filing? Options: Yes, pending regulatory inspection, Yes, legal or contractual hold, Yes, import/export license required, No known holds or pending inspections
• Do you have GMP-approved samples available for pilot, and if not, when will they be released? Options: GMP samples available now, Available within 2 weeks, Available within 1 month, Not available within 1 month
• Name the owner of data access and whether your LIMS or QA systems allow secure data transfer and electronic signatures. Options: LIMS with secure transfer and e-sign, LIMS with limited transfer, No LIMS integration, manual export only, Other
• State the number of dedicated FTEs your organization can assign to technical assessment and transfer execution phases. Options: 0 (no dedicated FTEs), 1-2, 3-5, 6-10, More than 10
• Select one: if a required infrastructure upgrade or qualified equipment is missing, will you fund it, delay the transfer, or pause the project? Options: Fund the upgrade or equipment, Delay the transfer for procurement, Pause the project until capability exists

Other options you are weighing

• What would need to be true for you to keep the current incumbent instead of switching to a new partner?
• Pick the alternatives you are actively evaluating: incumbent, internal execution, other CDMOs, licensing partner, or pause the project. Options: Incumbent supplier/site, Internal execution by your team, Other third-party CDMO(s), Licensing or technology partner, Pause or wait for more data
• Has anyone proposed executing the transfer internally without an outside partner, and if so, who and what is their proposed timeline? Options: Yes, internal team with timeline, Yes, internal intent but no timeline, No internal proposal
• Explain the incumbent strengths that would keep you with them, for example site familiarity, existing contracts, or completed comparability data.
• Would procurement be authorized to sign within two weeks if an external partner demonstrates required equivalence in the pilot? Options: Yes, procurement can sign within two weeks, No, additional approvals required, Possibly with expedited governance approval

Acceptance criteria and quick-stop decision points

• What single measurable acceptance criterion would make you sign off the validation package immediately?
• Provide the top five technical metrics or acceptance tests you require for batch acceptance and regulatory filing.
• Please map the roles that must sign technical acceptance and the roles that must sign commercial acceptance, and state their expected review timelines.
• Choose the batch failure threshold that would require rework, additional runs, or program pause. Options: Any critical failure requires rework, Up to 1 non-critical deviation allowed, Allow trend-based reconciliation, Require program pause after repeated failures
• Indicate whether, if acceptance shows a critical deviation, you will fund additional runs, accept a change control, or stop the project. Options: Fund additional runs, Accept change control and continue, Stop the project

Next steps and practical scheduling

• Highlight the single action that would accelerate contracting and mobilization if the technical assessment meets expectations.
• Share your preferred target dates for pilot start, pilot completion, and validation-ready submission.
• Please name the owner of vendor onboarding and the typical number of business days required.
• Detail the documents you will share within five business days of mutual commit, for example batch records, methods, and stability datasets.
• Is there a single approval that must occur before work can start, and how likely is that approval to clear within your target window? Options: Yes, highly likely within window, Yes, but timeline uncertain, No single gating approval required

• Solution Experience Session

• Confirm the current state and its cost to your team
• You confirm the demonstrated methodology removes the root causes of timeline slippage and regulatory risk you described.
• Deliver a tailored scenario run that shows expected timeline reduction, risk mitigations, milestones, and named owners based on the session inputs.
• Provide the latest process characterization documents, receiving-site equipment list, and target regulatory filing date.
• Define the operational success criteria
• You agree the scenario timelines and named owners are realistic and sufficient to meet the filing target.
• Walk through the structured transfer methodology mapped to your context
• You identify the remaining evidence and acceptance criteria needed before mutual commit.
• Agree on the technical decision criteria and the reviewers who will approve the validation campaign to proceed.
• Run two realistic scenarios using your constraints
• Validate the demonstration against your needs
• Agree next steps and decision criteria

• Solution Experience Session
• Solution Experience Deck
• Solution Brief

• meeting
• slides
• document

• Incoming Process Characterization
• Analytical Method Transfer and Validation
• Transfer and Qualification of Batch Records and SOPs
• Equipment Qualification and Factory/Site Acceptance Support
• Design and Install Equipment Modifications
• Pilot Technology‑Transfer Manufacturing Batches
• Commercial Process Validation Campaign Execution
• Aseptic Fill and Sterile Line Qualification
• Cleaning Validation Execution
• Critical Raw Material and Supplier Qualification
• Stability Study Execution and Reporting
• Training of Receiving Site Operations and Quality
• Regulatory Filing Package Assembly and Submission Support

Incoming Process Characterization

• Do you have a sending-site technical transfer package or master batch record that describes unit operations, target setpoints, and material inputs? Options: Yes, full technical transfer package, Partial batch record only, Only high-level SOPs, No formal package available
• Which sending-site documents are available to support characterization (select all that apply): master batch record, process flow diagram, critical quality attribute (CQA) list, critical process parameter (CPP) table, risk assessment (FMEA)? Options: Master batch record, Process flow diagram, CQA list, CPP table, Risk assessment (FMEA), None of the above
• How many representative lots, pilot runs, or scale-down model runs can you provide for analytical and process characterization (for example 3 validation lots, 1-scale down model)? Options: None available, 1-2 lots/runs, 3-5 lots/runs, More than 5 lots/runs
• Provide the current sending-site in-process control limits and final product release specifications (attach COAs or list numeric limits for assay, impurities, potency).
• Identify any specialized unit operations in the sending process that must be reproduced or emulated (for example lyophilization cycle, chromatography resin type, viral inactivation hold step).
• Is the critical raw material list and Certificate of Analysis (COA) for each input available to support incoming material comparability assessments? Options: All COAs provided, Partial COAs provided, COAs need to be obtained, Not applicable

Analytical Method Transfer and Validation

• Which analytical methods must be transferred and qualified at the receiving site (assay, impurities/by-products, potency, sterility, endotoxin, particulate), and which are stability indicating? Options: Assay, Impurities/by-products, Potency, Sterility, Endotoxin, Particulate, Stability indicating
• Do you have validated method documentation from the sending site (method SOP, system suitability, method validation report, acceptance criteria tied to ICH Q2(R1))? Options: Full validated method package, Method SOPs only, Partial validation data, No documentation available
• How many analytical methods require full revalidation versus transfer verification at the receiving-site laboratory? Options: All require full revalidation, Some require revalidation, some verification, Only verification required, Undetermined
• Provide the receiving-site laboratory capabilities relevant to your methods: HPLC/UPLC, GC, LC-MS, ELISA, qPCR, sterility testing, endotoxin (LAL/PN-ETA) and qualification status of instruments.
• Specify expected sample throughput and sample custody needs for transfer verification and routine release testing (samples per lot, timeline for results, LIMS intake required).
• Are there specific regulatory expectations for method validation you need us to follow (for example FDA guidance, EMA, ICH Q2(R1))? Options: FDA, EMA, ICH Q2(R1), Other / specify in comments

Transfer and Qualification of Batch Records and SOPs

• Which master batch record sections and SOPs must be templated or adapted for the receiving site (raw material handling, in-process checks, equipment setpoints, labeling and packaging instructions)?
• Do you require a gap analysis between the sending-site batch record and the receiving-site standard operating procedures to produce a redline and reconciliation plan? Options: Yes, full gap analysis, Yes, high-level gap analysis only, No gap analysis required
• How many controlled documents will need formal change control and versioning before pilot lots (for example master batch record, SOPs, QC methods)? Options: 1-5, 6-15, 16-30, More than 30
• Provide the required sign-off chain for issued batch records and SOPs at the receiving site (roles or titles such as QA reviewer, head of manufacturing, qualified person).
• Identify any regional regulatory requirements that must be represented directly in batch records or SOPs (for example EU Qualified Person release wording, US biologics specific declarations).
• Is electronic batch record (EBR) support required and which EBR system or LIMS integration points are needed for execution? Options: EBR required with integration, EBR preferred without integration, Paper-based acceptable

Equipment Qualification and Factory/Site Acceptance Support

• Do you have equipment lists and qualification status from the receiving site (IQ/OQ/PQ reports, equipment DQ documentation, calibration records)? Options: Complete equipment lists and IQ/OQ/PQ, Partial records, No equipment qualification records available
• Which specific pieces of equipment require new qualification or reconfiguration for the transfer (for example fermenter, chromatography skid, isolator, filling line)?
• How will factory acceptance testing (FAT) and site acceptance testing (SAT) be handled for custom or modified equipment and who can witness FAT remotely or onsite? Options: Onsite witness required, Remote witness acceptable, No witness required
• Provide the expected utilities and environmental requirements for the process (cleanroom classification, HVAC setpoints, USP water grades, compressed air specifications).
• Identify any supply-chain lead-time constraints for spare parts or critical consumables that could impact equipment qualification milestones.
• Is performance qualification (PQ) acceptance based on predefined process performance indicators (for example Cpk, yield threshold, impurity limits) that you will supply? Options: Yes, we will supply numeric PQ thresholds, No, thresholds to be negotiated, Not applicable

Design and Install Equipment Modifications

• Which design changes are anticipated to adapt receiving-site equipment to the incoming process (for example piping changes, addition of single-use manifolds, HVAC modifications)?
• Provide any existing P&ID (piping and instrumentation diagram), layout drawings, or change-control constraints we must follow during design and installation.
• Who at your site will be the technical approver for design drawings and mechanical completion certificates?
• Estimate the acceptable downtime window for installation activities on the receiving site production line (hours per day, consecutive days, blackout periods).
• Identify any validation or sterilization requirements for new materials of construction (for example 316L stainless, single-use assemblies) before use in production.
• Are site engineering change requests (ECRs) and permits (for example confined space, lockout/tagout) required to proceed with installation? Options: Yes - ECR and permits required, Only standard work permits, No special permits required

Pilot Technology‑Transfer Manufacturing Batches

• How many pilot batches do you anticipate to demonstrate process reproducibility at the receiving site before committing to validation lots? Options: None, go straight to validation, 1 pilot batch, 2-3 pilot batches, More than 3 pilots
• Provide target pilot batch sizes and scale factors relative to the sending-site commercial batch (for example 50%, 100%, 200%).
• Which sampling plan and in-process tests must be executed during pilot batches (for example hold-time samples, in-process potency, critical parameter monitoring frequency)?
• Attach or describe any special packaging, primary container, or closure system that must be qualified during pilot manufacturing.
• Indicate the expected analytic release timeline for pilot lots and whether accelerated stability samples must be pulled from pilot material.
• Which acceptance criteria will confirm that pilot batches are successful for progression to validation (for example yield > X%, impurity < Y ppm, sterility negative)?

Commercial Process Validation Campaign Execution

• How many validation lots are required by your regulatory filing strategy and by the receiving-site quality policy (for example 3 consecutive commercial-scale lots)? Options: 1 lot, 3 consecutive lots, 3 nonconsecutive lots, Other - specify
• Provide the predefined process performance metrics and numeric thresholds that will be used to establish validation success (for example specification limits, Cpk, yield thresholds).
• Which acceptance testing program must be executed for validation lots (release testing, stability sample collection, environmental monitoring, sterility assurance), and who signs final lot release?
• Specify the data package deliverables you require at validation completion (batch records, OOS investigations, validation summary report, traceability matrix).
• Estimate the production window and equipment availability needed to execute the planned validation campaign (dates or month ranges).
• Which acceptance criteria will be used to determine formal validation success and enable regulatory filing (for example passing all release tests and meeting stability-indicating trends)?

Aseptic Fill and Sterile Line Qualification

• Do you require aseptic line qualification including media fill, isolator qualification, and cleanroom classification mapping for the receiving site? Options: Full aseptic qualification including media fill, Partial qualification only, Aseptic not required
• Which primary container and closure systems must be qualified for sterile filling (for example vials, prefilled syringes, cartridges) and are container-closure integrity studies required?
• Provide the required environmental monitoring program for sterile operations (CF limits, differential pressures, particle counts, action limits).
• Who will perform or witness media fills and sterility validation runs and which roles must be present (for example QA witness, microbiologist)?
• Are sterility test method transfer and endotoxin limits part of the sterile line qualification scope? Options: Yes, both sterility and endotoxin transfer, Only sterility, Only endotoxin, No
• Indicate any container closure system constraints such as cold chain, nitrogen overlay, or dedicated filling isolator requirements.

Cleaning Validation Execution

• Which equipment and contact surfaces require cleaning validation (for example reactors, transfer lines, mixers, filling needles)?
• Specify the target residue acceptance limits and analytical endpoints for cleaning validation (for example % of therapeutic dose, health-based limits, TOC limits).
• Which sampling techniques must be used for cleaning verification (swab, rinse, ATP) and which analytical methods will support residue detection? Options: Swab sampling, Rinse sampling, ATP, TOC, HPLC for residue
• Provide any prior cleaning validation protocols or worst-case product matrices from the sending site to inform method sensitivity and sample sites.
• Are sequential cleaning studies for product families required to demonstrate non-cross-contamination across product suites? Options: Yes, No, Conditional/depends on product family
• Specify who will approve the cleaning validation conclusion report and any periodic revalidation intervals you require.

Critical Raw Material and Supplier Qualification

• Which critical raw materials and components require qualification or comparability assessment (for example active pharmaceutical ingredient, excipients, resin lots, single-use assemblies)?
• Which supplier documentation do you require before acceptance (COA, GMP certificate, audit reports, change control history)? Options: COA, GMP certificate, Audit reports, Change control history, None of the above
• How many supplier lots or qualification samples are needed to demonstrate equivalence for each critical raw material prior to pilot or validation runs? Options: None, 1-2 lots, 3-5 lots, More than 5 lots
• Provide any approved supplier list (ASL) constraints or single-source restrictions that limit material sourcing options.
• Which tests and acceptance limits do you require on incoming raw material COAs (for example assay, impurities, residual solvents, microbial limits)?
• Are on-site supplier audits required as part of supplier qualification and if so, which geographic regions or supplier tiers need auditing? Options: On-site audits required, Remote audits acceptable, No audits required

• Master Services Agreement (MSA)
• Statement of Work (SOW)
• Commercial Terms & Order Form
• Data Access Authorization & Data Processing Agreement (DPA)
• Project Governance & Change Control Agreement
• GMP & Regulatory Filing Addendum
• Site Access, Sample & Material Supply Agreement
• Acceptance Criteria & Release Protocol

• desired_state
• current_state
• stakeholders
• gaps
• success_criteria
• decision_readiness
• desired_state
• decision_readiness
• current_state
• success_criteria
• gaps
• stakeholders
• desired_state
• success_criteria
• stakeholders
• gaps
• current_state
• decision_readiness
• decision_readiness
• decision_readiness
• decision_readiness
• decision_readiness

• Go-live Health Check (weeks 1-4)
• First Measurement Review (weeks 4-10)
• Quarterly Operational Review
• Annual Success Review and Lessons Learned

• Move approved enhancement requests into the steady-state backlog with estimated delivery windows and success criteria.
• Confirm whether quarterly performance on validation batch first-pass acceptance rate and deviation closure within SLA meets or is progressing toward the targets recorded in Solution Scope.
• Prioritize enhancement requests and agree the implementation window for high-priority items.
• Update the outstanding issue burn-down plan with clear resolution timelines for escalated risks.
• Publish the quarter-to-date operational dashboard and prioritized enhancement backlog with estimated delivery windows.
• Document remediation steps and update the risk register for any items requiring executive escalation.
• Schedule targeted working sessions for any high-impact enhancements that require cross-functional alignment.
• Annual performance vs Solution Scope targets
• Formally record whether annual outcomes for time to regulatory submission and validation batch first-pass acceptance rate met the targets recorded in Solution Scope.
• Produce a documented lessons-learned summary with recommended playbook updates for future transfers.
• Confirm the ongoing shared channel for open issues and the governance model for enhancement requests and escalations.
• Publish the annual outcomes summary, including metric trends vs Solution Scope targets and the lessons-learned document.
• Create or confirm the shared issue-tracking channel and document the escalation path and response SLAs.
• Reconfirm acceptance criteria and owners recorded in Solution Scope
• All parties confirm the acceptance criteria and named owners recorded in Solution Scope are accurate and specific.
• Critical deployment checklist items and any missing prerequisites are identified and scheduled for completion.
• A prioritized list of blockers and immediate remediation actions with target dates is agreed.
• Publish the completed deployment validation checklist with outstanding items and target resolution dates.
• Open remediation tickets for each blocker with required acceptance criteria for closure and target dates.
• Share a short adoption-status note summarizing operator training completion and early process observations before the first measurement review.
• Present measurement data vs targets from Solution Scope
• Establish whether validation batch first-pass acceptance rate and time-to-release are trending toward the targets recorded in Solution Scope.
• Document root causes for shortfalls and agree corrective actions with target completion dates.
• Confirm the evidence required at the next checkpoint to validate remediation effectiveness.
• Publish the measurement dashboard snapshot and the root-cause analysis document for archived reference.
• Record the corrective action plan with specific verification steps and resolution timelines.
• Schedule the follow-up checkpoint and list the evidence to be provided for each remediated item.
• Operational metrics dashboard
• Deployment validation checklist review
• Persistent issue review and root causes
• Lessons learned and process improvements
• Root-cause analysis for gaps
• Open issues and enhancement backlog review
• Agree corrective action plan
• Early adoption and process health signals
• Enhancement request triage and prioritization
• Confirm timeline to next checkpoint
• Open issues burn-down and risk register update
• Establish shared channel and governance for ongoing issues
• Open issues and blocker triage
• Agree immediate remediation actions